Physician profile
Hammad N Qureshi
NPI 1063618874
$83,552.61
in general payments reported to CMS, 2019-2025
52 companies · $7,619 in 2025
The $7,619 reported for 2025 was more than what 91% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,799 · 2020: $13K · 2021: $26K · 2022: $11K · 2023: $15K · 2024: $8,764 · 2025: $7,619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Food and Beverage: $7,126 · Consulting Fee: $4,320 · Travel and Lodging: $2,350 · Education: $958.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,095.00 |
| Food and Beverage | $7,126.17 |
| Consulting Fee | $4,320.00 |
| Travel and Lodging | $2,350.40 |
| Education | $957.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $39,337.91 | 2019-2025 | Ofev, Jascayd |
| Astrazeneca Pharmaceuticals LP | $29,890.55 | 2019-2025 | Breztri, Tezspire, Airsupra |
| Intuitive Surgical, INC. | $3,612.24 | 2020-2025 | Da Vinci Sp |
| Electromed, INC. | $1,598.63 | 2022-2025 | Smartvest |
| Inspire Medical Systems, INC. | $1,236.92 | 2025 | Inspire |
| Actelion Pharmaceuticals US, INC. | $952.56 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Glaxosmithkline, LLC. | $851.56 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Abbvie INC. | $835.18 | 2022-2024 | |
| Mylan Specialty L.P. | $826.20 | 2019-2024 | Yupelri |
| Genzyme Corporation | $500.77 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $411.14 | 2019-2025 | Dupixent |
| Genentech USA, INC. | $319.16 | 2019 | |
| Mallinckrodt Hospital Products INC. | $299.34 | 2020-2025 | Acthar, Terlivaz |
| Galvanize Therapeutics, INC | $269.94 | 2025 | Aliya System |
| Merck Sharp & Dohme LLC | $209.06 | 2019-2024 | Keytruda, Winrevair |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $203.89 | 2022-2025 | Tezspire |
| Veran Medical Technologies, INC. | $188.05 | 2019-2020 | |
| Zoll Respicardia, INC. | $180.41 | 2021 | |
| Pulmonx Corporation | $145.31 | 2020-2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Tempus Ai, INC | $122.77 | 2025 | Xt Cdx |
| Novartis Pharmaceuticals Corporation | $108.27 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $105.19 | 2024-2025 | Aralast, Entyvio |
| Bayer Healthcare Pharmaceuticals INC. | $99.61 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $98.00 | 2023 | |
| Verona Pharma, INC. | $90.41 | 2025 | Ohtuvayre |
| Abbott Laboratories | $86.22 | 2021-2023 | Eterna |
| Gilead Sciences, INC. | $83.79 | 2021-2024 | Veklury |
| Grifols USA, LLC | $80.13 | 2019-2024 | Prolastin-C Liquid |
| Jazz Pharmaceuticals INC. | $79.63 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $70.26 | 2025 | Purified Cortrophin Gel |
| Astellas Pharma US INC | $66.93 | 2019-2025 | Veozah |
| Teva Pharmaceuticals USA, INC. | $59.94 | 2019 | |
| United Therapeutics Corporation | $58.84 | 2021-2023 | Tyvaso, Orenitram |
| Insmed, INC. | $56.83 | 2022-2025 | Arikayce |
| Philips North America LLC | $48.82 | 2019-2025 | Vest Therapy Und |
| Allergan, INC. | $43.94 | 2020 | |
| Viatris Specialty LLC | $41.54 | 2025 | Yupelri |
| Optinose US, INC. | $34.15 | 2019-2024 | |
| Inogen, INC. | $28.96 | 2025 | |
| Mallinckrodt Enterprises LLC | $28.55 | 2019 | |
| Harmony Biosciences LLC | $27.40 | 2020-2024 | |
| Shionogi INC | $24.88 | 2024 | Fetroja |
| Sunovion Pharmaceuticals INC. | $18.67 | 2019 | |
| Resmed Corp | $16.46 | 2025 | |
| Tactile Systems Technology INC | $14.34 | 2022 | |
| Cequr Corporation | $14.18 | 2025 | Cequr Simplicity |
| Almatica Pharma LLC | $13.60 | 2025 | Teriparatide |
| Pfizer INC. | $13.39 | 2023 | |
| Paratek Pharmaceuticals, INC. | $13.19 | 2023 | Nuzyra |
| Eisai INC. | $12.95 | 2020 | |
| Janssen Pharmaceuticals, INC | $11.07 | 2022 | |
| Ethicon US, LLC | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hammad Qureshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.